- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & Rapid Micro Methods (RMMs)
- Process Analytical Technology (PAT) & Quality by Design (QbD)
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Latest News
- Contact us
Pharma industry news
Two thirds of Britons would have genetic test to identify risk of disease if it were free on the NHS
Posted on: 29 January 2015 | Source: The Astellas Innovation Debate
Two thirds (66%) of the population would want to know whether they had a risk of developing a serious illness, such as cancer, if genetic testing were available for free on the NHS...
AstraZeneca announces four collaborations to use CRISPR technology for genome editing across its drug discovery platform
Posted on: 29 January 2015 | Source: AstraZeneca
AstraZeneca has announced 4 research collaborations aimed at harnessing CRISPR, a pioneering genome-editing technique, across its entire discovery platform...
Posted on: 28 January 2015 | Source: Frost & Sullivan
Frost & Sullivan says existing competitors’ dominance of the niche market raises entry barriers...
Posted on: 28 January 2015 | Source: Roche
Commenting on the Group’s results, Roche CEO Severin Schwan said: “We made good progress in 2014 with solid growth in both divisions driven by our newly launched medicines and diagnostic tests..."
Posted on: 28 January 2015 | Source: The Astellas Innovation Debate
British patients happy to have webcam consultations – especially the over 55s...
Posted on: 28 January 2015 | Source: GlobalData
The acromegaly and gigantism treatment market will expand at a modest Compound Annual Growth Rate (CAGR) of 3.74% from approximately $588 million in 2013 to $707 million by 2018, limited by a sparse pipeline, according to research and consulting firm GlobalData...
Posted on: 28 January 2015 | Source: Bristol-Myers Squibb Company
Bristol-Myers Squibb Company reported results for the fourth quarter and full year of 2014, which were highlighted by strong global sales for priority brands and important advances in the company’s immuno-oncology (I-O) portfolio...
Posted on: 28 January 2015 | Source: Andrew Lloyd & Associates
ProveDye is a new sterile solution of methylene blue designed to aid visualization in surgical procedures. With ProveDye, Provepharm extends the Proveblue® methylene blue compound product range...
Posted on: 27 January 2015 | Source: Frost & Sullivan
Country-specific EHR implementation strategies will expedite market development, says Frost & Sullivan...
Posted on: 27 January 2015 | Source: Actavis
Actavis plc and the owners of Auden Mckenzie Holdings Limited, a dynamic and fast growing company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the UK, announced that they have reached a definitive agreement, under which Actavis will acquire Auden Mckenzie for approximately £306 million in cash...
Posted on: 27 January 2015 | Source: Lukats and Shapiro
Half of UK bosses tempted to snoop on employees health app data to catch them ‘pulling a sickie’...
Posted on: 27 January 2015 | Source: Health Consumer Powerhouse
In spite of financial crisis, European healthcare keeps improving – but the equity gap widens...